Deniker P, Eyquem A, Bernheim R, Loo H, Delarue P
Neuropsychobiology. 1978;4(5):270-5. doi: 10.1159/000117640.
The study of the levels of thyroid antibodies was conducted in 58 patients treated with lithium and in 40 subjects who received other psychotropic drugs and who were used as controls. The measure of the antithyroglobulin antibodies were made by passive hemagglutination and that of the antimicrosomal antibodies by indirect immunofluorescence. For the whole control group, the research of the antithyroglobulin antibodies was positive in 3 cases, i.e. 7.5%. For the 58 patients treated with lithium, this research was positive in 11 subjects, i.e. 19%: thus, lithium seems to cause immunological reactions in the thyroid. 5 lithium-treated patients developed a goiter. The antibody determination was positive in only 2 subjects and was negative in the others. The measure of antithyroid antibodies before lithium did not enable us to predict the emergence of thyroid complications. On the contrary, subjects treated with lithium presented signficantly high antibody levels without developing clinical thyroid manifestations.
对58例接受锂治疗的患者以及40例接受其他精神药物治疗并作为对照的受试者进行了甲状腺抗体水平研究。抗甲状腺球蛋白抗体采用被动血凝法检测，抗微粒体抗体采用间接免疫荧光法检测。在整个对照组中，抗甲状腺球蛋白抗体检测呈阳性的有3例，即7.5%。在58例接受锂治疗的患者中，该检测呈阳性的有11例，即19%：因此，锂似乎会引发甲状腺的免疫反应。5例接受锂治疗的患者出现了甲状腺肿大。抗体检测仅在2例受试者中呈阳性，其他受试者均为阴性。锂治疗前的抗甲状腺抗体检测无法让我们预测甲状腺并发症的出现。相反，接受锂治疗的受试者抗体水平显著升高，但未出现临床甲状腺表现。
